

# Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety

NCT07185503

---

**Status** RECRUITING  
**Sponsor** Institute of Hematology & Blood Diseases Hospital, China  
**Enrollment** 60 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- Confirmed diagnosis of a hematologic malignancy (e.g., leukemia, lymphoma, myelodysplastic syndrome).
- Proven, probable, or possible invasive mucormycosis according to the 2019 European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria.
- Age ≥18 years and ≤65 years at enrollment.
- Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score of 0-2.
- No clinically significant organ dysfunction (e.g., renal, hepatic, cardiac) at screening that would preclude protocol-defined therapies.

... and 1 more (see full listing online)

### Exclusion (10)

- Prior treatment with non-liposomal amphotericin B formulations (e.g., amphotericin B deoxycholate) for ≥4 days.
- Documented hypersensitivity, severe immediate allergic reaction, or intolerance to liposomal amphotericin B.
- History of a second malignancy (other than the index hematologic malignancy) treated within the past 3 years.
- Active HIV infection, hepatitis B virus (HBV) infection (HBsAg-positive), hepatitis C virus (HCV) infection (RNA-positive), or syphilis.
- Psychiatric disorders, cognitive impairment, or other conditions impairing compliance with study procedures or assessments.

... and 5 more (see full listing online)

## Locations (9 total)

---

The Second Hospital of Dalian Medical University, Dalian, China  
The First Affiliated Hospital of Harbin Medical University, Harbin, China  
Shengjing Hospital of China Medical University, Shenyang, China  
... and 6 more locations